Trump Imposes Up to 100% Tariff on Patented Pharmaceutical Imports

Trump signed an executive order under Section 232 imposing up to 100% tariffs on patented pharmaceutical products and active pharmaceutical ingredients, aimed at forcing onshoring of drug manufacturing. Exemptions apply to generics, biosimilars, and orphan drugs. The pharmaceutical industry warned of significant price increases and threats to US investment. The order accelerates pressure on major drugmakers to relocate manufacturing to the United States.